On October 1, 2018 NewLink Genetics Corporation (NASDAQ:NLNK) reported that two abstracts were accepted for presentation at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) 33rd Annual Meeting being held November 7-11, 2018 in Washington, D.C (Press release, NewLink Genetics, OCT 1, 2018, View Source [SID1234529909]). These poster presentations will feature pharmacokinetic (PK) data from the Company’s Phase 1a study of NLG802, a prodrug of indoximod, in patients with advanced solid tumors and biomarker data from its Phase 2 study of indoximod in combination with checkpoint inhibition for patients with advanced melanoma. These data will be available during poster sessions on November 9 and 10, 2018.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Abstracts to be Presented at SITC (Free SITC Whitepaper) 2018:
Abstract 11213: A phase 1a clinical trial of NLG802, a prodrug of indoximod with enhanced pharmacokinetic properties, Rixe, O., et al.
Abstract 10294: The immunogenomic impact of indoximod on the tumor microenvironment of melanoma patients, Yu, J., et al.
About Indoximod
Indoximod is an investigational, orally available small molecule targeting the IDO pathway. The IDO pathway is a key immuno-oncology target involved in regulating the tumor microenvironment and immune escape. Indoximod is being evaluated in combination with treatment regimens including chemotherapy, radiation, checkpoint blockade and cancer vaccines across multiple indications such as acute myeloid leukemia (AML), diffuse intrinsic pontine glioma (DIPG) and melanoma.
About NLG802
NLG802 is a prodrug of indoximod. NLG802 has been shown in preclinical trials to increase bioavailability and exposure to indoximod above the levels achievable by direct administration of indoximod. NLG802 is currently being evaluated in clinical trials.